Other substances

VS12

A protease inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

VS12 is an experimental SARS-CoV-2 3C-like protease (possibly covalent) inhibitor (Guo et al., 2021).

VS12 on PubChem

Synonyms

3-[(5-Amino-1,3,4-thiadiazol-2-yl)sulfanyl]-1-(1-naphthyl)-2,5-pyrrolidinedione; Oprea1_434896

 

Structure image - VS12

C1C(C(=O)N(C1=O)C2=CC=CC3=CC=CC=C32)SC4=NN=C(S4)N

Supporting references

Link Tested on Impact factor Notes Publication date
Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation
3CLpro Small molecule Enzyme assay In vitro In silico 		in silico; in vitro enzyme assay 4.83

The compound inhibited SARS-CoV-2 3C-like protease (Mpro) in vitro in a dose dependent manner with an IC50 of 1.89 μM. Based on computational modelling and the observation that time of incubation decreases the measured IC50 value in an enzyme assay, V12 was predicted to inhibit Mpro covalently.

 Feb/24/2021
Export (.csv)